Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

GALT stock hub

Galectin Therapeutics Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

GALTis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

138.2M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

GALT

In the news

Latest news · GALT

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC-166.1

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All GALT market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

175

Groups with data

Currency

USD

Showing 175 of 175 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001133416
Company name	Galectin Therapeutics Inc.
Country	United States
Country code	US
Cusip	363225202
Employees	9
Employees Change	-6%
Employees Change Percent	-40
Enterprise value	$258.2M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US3632252025
Last refreshed	2026-05-10
Market cap	$138.2M
Market cap category	Micro-Cap
Price	$2.09
Price currency	USD
Sector	Healthcare
Sic	2834
Symbol	GALT
Website	https://galectintherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-22.41%

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Net Income	$-31M
Net Income Growth Quarters	4%
Net Income Growth Years	1%
Profit Per Employee	$-3.4M
ROA	-67.81
Roa5y	-81.77
ROCE	-174.6
ROIC	-166.1

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	5.28%
Cagr15y	-8.99%
Cagr1y	33.15%
Cagr20y	-10.83%
Cagr3y	6.71%
Cagr5y	-12.18%
EPS Growth Quarters	4
EPS Growth Years	1
Revenue Growth Years	0x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Assets	$19.5M
Cash	$17.7M
Current Assets	$19.4M
Current Liabilities	$8M
Debt	$137.7M
Equity	$-126.2M
Interest Coverage	-2.74
Liabilities	$145.7M
Long Term Assets	$96,000
Long Term Liabilities	$137.7M
Net Cash	$-120M
Net Cash By Market Cap	$-86.81
Tangible Book Value	$-128.4M
Tangible Book Value Per Share	$-1.97
WACC	5.48

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	2.42
Net Working Capital	$-6.3M
Quick ratio	2.21
Working Capital	$11.4M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-2.56%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	67.2%
1Y total return	33.12%
200-day SMA	3.93
3Y total return	21.51%
50-day SMA	2.63
50-day SMA vs 200-day SMA	50under200
5Y total return	-47.75%
All Time High	38.28
All Time High Change	-94.54%
All Time High Date	2003-09-12
All Time Low	0.3
All Time Low Change	596.67%
All Time Low Date	2009-01-12
ATR	0.16
Beta	0.45
Beta1y	-0.8
Beta2y	0.8
Ch YTD	-49.76
High	2.13
High52	7.13
High52 Date	2025-12-17
High52ch	-70.69%
Low	2.07
Low52	1.21
Low52 Date	2025-05-16
Low52ch	72.73%
Ma50ch	-20.47%
Premarket Change Percent	5.69
Premarket Price	$2.23
Premarket Volume	734
Price vs 200-day SMA	-46.82%
RSI	36.76
RSI Monthly	44.76
RSI Weekly	33.45
Sharpe ratio	0.74x
Sortino ratio	1.33
Total Return	-2.56%
Tr YTD	-49.76
Tr15y	-75.64%
Tr1m	-4.57%
Tr1w	-7.93%
Tr3m	-25.36%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-0.06
Operating Income	$-20.1M
Price target	$8.5
Price Target Change	$307

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	47,157,436%
Float Percent	71.64%
Net Borrowing	21,000,000
Shares Insiders	19.83%
Shares Institutions	18.46%
Shares Out	65,827,448
Shares Qo Q	0.84%
Shares Yo Y	2.56%
Short Float	15.82%
Short Ratio	24.03
Short Shares	11.34

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	291,870.85x
Bv Per Share	-1.97
Ch10y	67.2
Ch15y	-75.64
Ch1m	-4.57
Ch1w	-7.93
Ch1y	33.12
Ch20y	-89.9
Ch3m	-25.36
Ch3y	21.51
Ch5y	-47.75
Ch6m	-59.81
Change	-0.95%
Change From Open	-1.88
Close	2.11
Days Gap	0.95
Depreciation Amortization	53,000
Dollar Volume	433,652
Earnings Date	2026-05-15
Earnings Time	bmo
EBIT	$-20.1M
EPS	$-0.48
F Score	2
Financing CF	26,475,000
Fiscal Year End	December
Founded	2,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-03-31
Last Report Date	2025-12-31
Last Split Date	2012-03-23
Last Split Type	Reverse
Last10k Filing Date	2026-03-31
Ma150	3.85
Ma150ch	-45.7%
Ma20	2.31
Ma20ch	-9.68%
Net CF	2,600,000
Next Earnings Date	2026-05-22
Open	2.13
Optionable	Yes
Position In Range	33.33
Post Close	2.09
Postmarket Change Percent	0.48
Postmarket Price	$2.1
Ppne	22,000
Pre Close	2.11
Price Date	2026-05-08
Relative Volume	0.71x
Share Based Comp	1,659,000
Tr20y	-89.9%
Tr6m	-59.81%
Us State	Georgia
Volume	207,489

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does GALT pay a dividend?

Capital-return profile for this ticker.

Performance

GALT stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns GALT?

Insider, institutional, and short-interest positioning.

Institutional ownership

+18.5%

Float: +71.6% of shares outstanding

Insider ownership

+19.8%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

GALT momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

36.8

Neutral momentum band

Price vs 200-day MA

-46.8%

50/200-day relationship not available

Beta (5Y)

0.45

Less volatile than the market

Sharpe ratio

0.74

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About GALT

Hub-level FAQ points readers to the deeper analysis pages.

What is the current GALT stock rating?

Galectin Therapeutics Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full GALT analysis?

The full report lives at /stocks/GALT/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for GALT?

The latest report frames GALT around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the GALT page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.